2026 Charles G. Drake: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	112	442	408	271	246	521	86820
Medicine	112	5039	4725	2730	2528	524	86821

Overview

Charles G. Drake is affiliated with Columbia University in the United States and has contributed extensively to the fields of medicine and immunology. Their research encompasses oncology, pulmonary and respiratory medicine, immunology, molecular biology, and surgery, with a significant focus on cancer and immune-related topics.

The scientist's main areas of study include:

Medicine
Immunology and Microbiology

Within these broader disciplines, their subfields of expertise are:

Oncology
Pulmonary and Respiratory Medicine
Immunology
Molecular Biology
Surgery

Drake's research topics concentrate on cancer and immunotherapy, specifically:

Cancer Immunotherapy and Biomarkers
Prostate Cancer Treatment and Research
Immunotherapy and Immune Responses
Renal cell carcinoma treatment
Immune cells in cancer
Bladder and Urothelial Cancer Treatments
CAR-T cell therapy research

The scientist has published in several frequent venues, indicating a consistent presence in prominent journals:

Journal of Clinical Oncology
Cancer Research
The Prostate
Clinical Cancer Research
European Urology

Noteworthy recent papers authored or co-authored by Drake include:

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020, European Urology)
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages (2021, Cell)
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens (2020, Nature Biotechnology)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020, Journal for ImmunoTherapy of Cancer)
Prostate carcinogenesis: inflammatory storms (2020, Nature reviews. Cancer)

The scientist maintains collaborative relationships with several frequent co-authors including:

Aleksandar Obradović
Andrea Califano
Matthew G. Chaimowitz
Matthew C. Dallos
Angelo M. De Marzo

Drake's publication record reflects a sustained focus on cancer immunotherapy, prostate cancer, and immune-based treatment strategies, contributing both to clinical and molecular understandings of cancer biology. Their work spans fundamental studies of tumor microenvironments and immune responses to translational research aimed at improving therapeutic interventions.

Best Publications

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

14371
Citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

9134
Citations
Immune checkpoint blockade: a common denominator approach to cancer therapy

Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll

4422
Citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

3544
Citations
A draft map of the human proteome

Min Sik Kim;Sneha M. Pinto;Derese Getnet;Raja Sekhar Nirujogi

2565
Citations
Inflammation in prostate carcinogenesis

Angelo M. De Marzo;Angelo M. De Marzo;Elizabeth A. Platz;Siobhan Sutcliffe;Jianfeng Xu

2090
Citations
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

1902
Citations
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Seng Ryong Woo;Meghan E Turnis;Monica V Goldberg;Jaishree Bankoti

1833
Citations
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Suzanne L Topalian;Charles G Drake;Drew M Pardoll

1642
Citations
Role of LAG-3 in regulatory T cells.

Ching Tai Huang;Creg J. Workman;Dallas Flies;Xiaoyu Pan

1612
Citations
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Wenhua Gao;Martin H. Voss;Martin H. Voss

1263
Citations
LAG3 (CD223) as a cancer immunotherapy target.

Lawrence P. Andrews;Ariel E. Marciscano;Charles G. Drake;Dario A. A. Vignali

1061
Citations
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Jing Zeng;Alfred P. See;Jillian Phallen;Christopher M. Jackson

1029
Citations
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

Andrew B Sharabi;Andrew B Sharabi;Michael Lim;Michael Lim;Theodore L DeWeese;Theodore L DeWeese;Charles G Drake;Charles G Drake

897
Citations
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

877
Citations
Mechanisms of immune evasion by tumors.

Charles G. Drake;Elizabeth Jaffee;Drew M. Pardoll

870
Citations
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

Sofia Lyford-Pike;Shiwen Peng;Geoffrey D. Young;Janis M. Taube

845
Citations
Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity

Timothy J. Harris;Joseph F. Grosso;Hung Rong Yen;Hong Xin

729
Citations
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Charlene M Fares;Eliezer M Van Allen;Charles G Drake;James P Allison

709
Citations
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Evan J. Lipson;William H. Sharfman;Charles G. Drake;Ira Wollner

653
Citations
Prostate cancer

Unknown

549
Citations

Frequent Co-Authors

Emmanuel S. Antonarakis University of Minnesota

Angelo M. De Marzo Johns Hopkins University School of Medicine

Drew M. Pardoll Johns Hopkins University School of Medicine

George J. Netto University of Alabama at Birmingham

Elizabeth A. Platz Johns Hopkins University

Janis M. Taube Johns Hopkins University

Phuoc T. Tran Johns Hopkins University School of Medicine

Tullia C. Bruno University of Pittsburgh

Toni K. Choueiri Harvard University

Michael A. Carducci Johns Hopkins University

External Links

Personal website of Charles G. Drake

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to a variety of interdisciplinary career paths, including advanced nursing degrees that complement immunology expertise. Many professionals pursue nurse practitioner roles to gain hands-on clinical experience. For those considering this route, exploring the easiest np program options online can help balance rigorous immunology studies with practical nursing education.

Particularly for those interested in mental health, online psychiatric nurse practitioner programs offer specialized training that leverages an understanding of immune system interactions with psychological conditions. Programs known for the best pmhnp programs online often provide excellent clinical placements, crucial for real-world experience.

Cost is another significant factor for students and professionals advancing their education. Identifying the cheapest online pmhnp certificate programs can make pursuing specialized immunology-related healthcare careers more accessible and financially feasible.

Knowing the potential financial outcomes, such as how much a Doctor of Nursing Practice (DNP) can make, is essential when choosing a career pathway. Understanding the how much does a dnp make metric helps graduates make informed decisions about their education investments and professional goals within immunology and healthcare.